# Predictimmune

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/predictimmune

- Industry: Healthcare IT
- Headquarters: Cambridge, UK
- Website: www.predictimmune.com
- Total disclosed funding: $18M
- Latest round: Series B (Jul 30, 2019)
- Investors on record: 5

## About

Predictimmune Limited develops advanced diagnostic solutions focused on improving patient outcomes in autoimmunity and transplant medicine through innovative testing methods.Predictimmune Limited, founded in 2017, is headquartered in Cambridge, UK. The company specializes in diagnostics aimed at predicting disease progression and treatment responses for patients with complex immunological conditions. In July 2019, Predictimmune raised GBP 10 million in Series B funding, co-led by Cambridge Enterprise and Parkwalk Advisors, marking a significant milestone in its financial growth. The firm has executed a total of 4 deals since its inception.Predictimmune focuses on providing advanced diagnostic solutions aimed at enhancing patient outcomes in autoimmunity and transplant medicine. Their core product offerings include innovative tests designed to predict disease progression and treatment responses in patients suffering from complex immunological conditions. These tests leverage proprietary algorithms and biomarkers to offer clinicians actionable insights, facilitating personalized treatment plans that target specific patient needs. The company's clientele includes healthcare providers, hospitals, and research institutions that utilize these diagnostics in various geographical markets, notably in North America and Europe.In 2023, Predictimmune reported revenue of GBP 0, with an EBITDA of GBP -2,260,632.40. The company's revenue generation is primarily derived from the sale of their diagnostic products through a B2B model, where healthcare providers and institutions engage with the company to acquire testing services. The transaction structure typically involves direct sales agreements and service contracts, allowing clients to access Predictimmune's proprietary diagnostic tests as part of their patient care protocols.Predictimmune intends to leverage the GBP 10 million raised in Series B funding to further develop its pipeline of diagnostic products and expand into new markets. The company is focused on enhancing its test offerings, with plans for release in the coming years, while targeting expansion in North America and Europe by 2024. This strategy aims to address the growing demand for advanced diagnostic solutions in managing autoimmune disorders and organ transplant monitoring.

## Funding rounds

- Series B, Jul 30, 2019, $12M — Cambridge Enterprise, BGF Investment Management, Parkwalk Advisors, Cambridge Innovation Capital
- Series A, May 4, 2017, $6.1M — Cambridge Enterprise, Parkwalk Advisors, Wren Capital

## Investors

- Cambridge Enterprise — Series A, Series B
- Parkwalk Advisors (https://capitalatlas.ai/funds/parkwalk-advisors) — Series A, Series B
- Wren Capital (https://capitalatlas.ai/funds/wren-capital) — Series A
- BGF Investment Management (https://capitalatlas.ai/funds/bgf-investment-management) — Series B
- Cambridge Innovation Capital (https://capitalatlas.ai/funds/cambridge-innovation-capital) — Series B